SCHEDULE 13G: Nantahala Capital Management Discloses 9.99% Stake in Grace Therapeutics, Inc.

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in Grace Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed a Schedule 13G, reporting beneficial ownership of Grace Therapeutics, Inc. common stock.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 1,391,773 shares of Grace Therapeutics, Inc. common stock.
• This ownership represents 9.99% of the total outstanding common stock of Grace Therapeutics, Inc.
• The reported shares include 213,570 shares that can be acquired within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC is classified as an investment adviser, while Wilmot B. Harkey and Daniel Mack are classified as control persons.
• The Reporting Persons hold shared voting power and shared dispositive power over all 1,391,773 shares.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, holds the right to receive dividends or proceeds from more than 5% of the beneficially owned shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable investment firm like Nantahala Capital Management is generally viewed positively by the market, indicating investor confidence. However, the document itself does not contain operational or financial performance details of the issuer.

Positives

• A significant stake by an institutional investor like Nantahala Capital Management can signal confidence in the company's long-term prospects.
• The investment is stated to be held in the ordinary course of business, not for the purpose of changing or influencing control, suggesting a passive, investment-focused position.

Risks

• The document does not detail specific risks related to Grace Therapeutics, Inc.'s operations or financial health, as it is a beneficial ownership report.

Future Outlook

This document, a Schedule 13G, does not provide any forward-looking statements or guidance regarding Grace Therapeutics, Inc.'s future outlook.

Industry Context

The filing indicates a significant investment by a specialized investment firm in a biotechnology or pharmaceutical company (Grace Therapeutics, Inc.), which is common in the healthcare sector where long-term investments are often made based on pipeline potential or market positioning. This type of passive investment typically reflects a belief in the company's underlying value without intent to influence management.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a nearly 10% stake could be perceived positively, potentially boosting investor confidence and signaling a belief in the company's value.
• Management: The filing indicates a passive investment, meaning the investor does not intend to influence or change control of the issuer, which allows current management to continue their strategic direction without immediate external pressure from this specific shareholder.

Key Dates

Keywords

Grace Therapeutics Inc., Nantahala Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Institutional Investor, Warrants, Equity Stake